These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 22189841

  • 1. The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy.
    Hirst JA, Taylor KS, Stevens RJ, Blacklock CL, Roberts NW, Pugh CW, Farmer AJ.
    Kidney Int; 2012 Apr; 81(7):674-83. PubMed ID: 22189841
    [Abstract] [Full Text] [Related]

  • 2. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.
    Fegan PG, Davis WA, Kamber N, Sivakumar S, Beilby J, Davis TM.
    Diabet Med; 2011 Jul; 28(7):849-55. PubMed ID: 21231957
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis.
    Blacklock CL, Hirst JA, Taylor KS, Stevens RJ, Roberts NW, Farmer AJ.
    Diabet Med; 2011 Oct; 28(10):1182-7. PubMed ID: 21627686
    [Abstract] [Full Text] [Related]

  • 5. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Jin SM, Han KA, Yu JM, Sohn TS, Choi SH, Chung CH, Park IeB, Rhee EJ, Baik SH, Park TS, Lee IK, Ko SH, Hwang YC, Cha BS, Lee HW, Nam MS, Lee MK.
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
    [Abstract] [Full Text] [Related]

  • 6. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P, Rossing K, Parving HH.
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [Abstract] [Full Text] [Related]

  • 7. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D.
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [Abstract] [Full Text] [Related]

  • 8. Meta-Analysis of the Effect of Dietary Sodium Restriction with or without Concomitant Renin-Angiotensin-Aldosterone System-Inhibiting Treatment on Albuminuria.
    D'Elia L, Rossi G, Schiano di Cola M, Savino I, Galletti F, Strazzullo P.
    Clin J Am Soc Nephrol; 2015 Sep 04; 10(9):1542-52. PubMed ID: 26240299
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
    Nielsen SE, Persson F, Frandsen E, Sugaya T, Hess G, Zdunek D, Shjoedt KJ, Parving HH, Rossing P.
    Diabet Med; 2012 Aug 04; 29(8):e184-90. PubMed ID: 22268920
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system.
    Hollenberg NK.
    J Hypertens Suppl; 1997 Dec 04; 15(7):S7-13. PubMed ID: 9532515
    [Abstract] [Full Text] [Related]

  • 13. Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.
    Uzu T, Araki SI, Kashiwagi A, Haneda M, Koya D, Yokoyama H, Kida Y, Ikebuchi M, Nakamura T, Nishimura M, Takahara N, Obata T, Omichi N, Sakamoto K, Shingu R, Taki H, Nagai Y, Tokuda H, Kitada M, Misawa M, Nishiyama A, Kobori H, Maegawa H, Shiga Committee for Preventing Diabetic Nephropathy.
    PLoS One; 2016 Dec 04; 11(12):e0164936. PubMed ID: 28033332
    [Abstract] [Full Text] [Related]

  • 14. Viper venom for diabetic nephropathy.
    Caramori ML.
    Kidney Int; 2012 Apr 04; 81(7):615-6. PubMed ID: 22419043
    [Abstract] [Full Text] [Related]

  • 15. Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness.
    Farmer AJ, Stevens R, Hirst J, Lung T, Oke J, Clarke P, Glasziou P, Neil A, Dunger D, M Colhoun H, Pugh C, Wong G, Perera R, Shine B.
    Health Technol Assess; 2014 Feb 04; 18(14):1-128. PubMed ID: 24576414
    [Abstract] [Full Text] [Related]

  • 16. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK, Dormanesh B, Sagheb MM, Roozbeh J, Vessal G, Pakfetrat M, Daneshbod Y, Kamali-Sarvestani E, Lankarani KB.
    Am J Kidney Dis; 2012 Dec 04; 60(6):896-903. PubMed ID: 22770926
    [Abstract] [Full Text] [Related]

  • 17. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME.
    J Hypertens Suppl; 1996 Dec 04; 14(6):S11-4. PubMed ID: 9023709
    [Abstract] [Full Text] [Related]

  • 18. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
    Sternlicht H, Bakris GL.
    Blood Purif; 2016 Dec 04; 41(1-3):139-43. PubMed ID: 26766168
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
    Fernández-Juárez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Lahera V, Casas L, Oliva J, PRONEDI Study Group.
    Clin J Am Soc Nephrol; 2013 Nov 04; 8(11):1870-6. PubMed ID: 24135218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.